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Abstract
Background: Oral complications may be observed during chemotherapy and are important side effects that may
directly affect the anticancer treatment, even causing septicaemia in some cases. This research was done in order
to evaluate changes in oral lesions during follow-up of children and adolescents in chemotherapy at Hospital
Estadual Infantil Nossa Senhora da Glória (HEINSG).
Methods: The study design was longitudinal, 45 patients were evaluated and monitored for 1 month after the
initiation of chemotherapy. Twenty-eight patients were male and 17 female, ranging from 3 months to 18 years
old.
Results: The results show an increase in the number of mucositis cases and a decrease in xerostomia cases after
the initiation of treatment, and other oral lesions were also found in low numbers.
Conclusions: It is possible to avoid oral complications by maintaining a good oral health, and reducing infectious
outbreaks. It is also feasible to obtain an early diagnosis of, and treat these oral complications, preventing them
from following a more severe clinical course that may negatively affect the individual’s treatment. This outcome
requires the presence of a dental surgeon on the multidisciplinary cancer treatment team.
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Background
Cancer is a term used to describe a group of diseases
that involve the uncontrolled growth of cells [1]. In re-
cent decades, cancer has become a serious global public
health problem. The World Health Organisation (WHO)
has estimated that in the year 2030, there will be 27 mil-
lion incident cases of cancer, 17 million deaths from
cancer, and 75 million people each year living with
cancer. The regions most affected by these increases are
developing countries [2].
Infant-juvenile cancers differ from adult cancers in
many respects, such as types, sites, aetiologies, charac-
teristics, and treatments [1].
Neoplasms were the leading cause (7 %) of deaths due
to morbidity in children and adolescents (1–19 years) in
2011 and were surpassed by only deaths due to external
causes. This fact is particularly troubling when one con-
siders that younger individuals comprise a large propor-
tion of the Brazilian population. According to information
from the last population census in 2010, approximately
30 % of the population is below the age of 19 [3].
According to population-based cancer records (Regis-
tros de Câncer de Base Populacional), the percentage of
paediatric tumours observed in Brazil is 3 %. Approxi-
mately 11,840 new cases of cancer in children and ado-
lescents up to 19 years of age have been estimated in
Brazil for 2014 [3].
There has been an improvement in the survival rates
of children with cancer due to dosage intensification and
the combination of chemotherapy drugs, which has also
led to success in the cancer treatment healing response
[4–6]. Chemotherapy acts by destroying or inhibiting
the growth of rapidly multiplying cells, without differen-
tiating cancer cells, which proliferate rapidly, from
normal cells, such as the oral mucosa [7].
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Chemotherapy is used to treat approximately 70 % of
cancer patients [6, 8]. Of these patients, 40 % develop
oral manifestations, and this number increases to over
90 % in children under 12 years of age [7, 9].
The following oral manifestations related to anticancer
treatment are commonly found: mucositis, xerostomia
[10, 11], infections, salivary gland dysfunction, dysgeusia,
and pain [12].
Given that most infant-juvenile patients with malignan-
cies receive chemotherapy, which is often associated with
side effects consisting of oral complications, this study
aimed to evaluate changes over the course of two moni-
toring sessions in the oral manifestations of children and
adolescents receiving chemotherapy at the Hospital Esta-
dual Infantil Nossa Senhora da Glória (HEINSG).
Methods
This study had a longitudinal design and was performed
by monitoring children and adolescents aged up to
18 years and 364 days who had received their first can-
cer diagnosis and had started chemotherapy at HEINSG
between April 2013 and 2014. The individuals were eval-
uated on two occasions approximately 1 month after the
initiation of chemotherapy.
When individuals were admitted to HEINSG and diag-
nosed with a malignant neoplasm, at the first study
stage, an interview and clinical examination were per-
formed before or within 3 days of starting chemother-
apy. At this stage, data regarding oral health and
sociodemographic characteristics, such as gender, age,
place of birth, education, maternal education, and socio-
economic status, were collected.
The HEINSG serves its patients only by the Unified
Health System (SUS) and it is located the only reference
center of public state network for cancer treatment in
children and adolescents. Being a public referral hospital
usually the patients treated are less favored socioeco-
nomic status.
The Economic Classification of individuals followed the
New Economic Classification Standard Criteria of Brazil,
which aims to discriminate large groups of people accord-
ing to their consumption capacity of accessible products
and services to a significant portion of the population and
classify households, assuming, as an assumption that the
class is a familiar feature among others. According to this
criterion individuals can be classified into five classes A, B,
C, D and E, and class A is the best economic status and
class E the worst economic condition [13].
Some information, such as the indicated treatment
and diagnosis, was collected from the patient’s medical
records.
For information about xerostomia, mucositis, oral can-
didiasis, herpes simplex and cold sore, a clinical examin-
ation was conducted after completing the interview. All
patients were examined in HEINSG dependencies by the
same operator, which was a dentist (DBV), thus, dimin-
ishing the interobserver variation. A preparation was
made through pictures of the most common oral alter-
ations that would be expected to be found in the study
group.
Through sialometry it is possible to evaluate the pro-
duction of unstimulated saliva, or by chemical, mechan-
ical or gustatory stimulation [14]. Individuals commonly
produce 0.3 ml/min of saliva without stimulation; when
secretion is less than or equal to 0.1 ml/min, it is charac-
terised as hyposalivation [15].
An adaptation was made to the criteria proposed by
the World Health Organization [16], a scale test that
consists in measuring the production of saliva produced
for one minute in a graph vessel (0 to 3 ml), to diagnose
hyposalivation [14]. The test was performed after 1.5 to
2 h in which the patient should not have smoked, drunk,
washed his mouth or swallowed food.
When the sialometry test performed in patients ob-
tained a measure less than 0.3 ml/min. saliva, and more-
over were present the symptoms described in any of
degrees of severity scale used to quantify the xerostomia
as a side effect (Table 1) proposed by the World Health
Organization (WHO) xerostomia was considered present
and was considered absent when the test there was a
greater extent 0.3 ml/min and was also not observed any
symptoms.
Xerostomia was only evaluated in children aged 6
years or more and in adolescents.
Mucositis was diagnosed via clinical examination by
evaluating the appearance of the oral mucosa. Mucositis
was not graded according to severity but was considered
absent or present according to whether a change in the
mucosa was noted on any of the severity scales (discol-
oration, erythema, pseudomembrane, or deep ulceration)
proposed by the WHO [16].
Complications including oral candidiasis, labial herpes
simplex, and mouth ulcers were evaluated by visual clin-
ical examination [17].
Table 1 Quantification of xerostomia as a side effect according
to WHO
Degrees of severity of xerostomia
Grade 1 Symptomatic (thick or sparse saliva) without significant
dietary changes, saliva production unstimulated >0.2 ml/min.;
Grade 2 Symptomatic with significant changes in the oral intake
(copious intake of water or use of other lubricants, limited
to purees diet and/or soft and wet food); unstimulated saliva
production from 0.1 to 0.2 ml/min.;
Grade 3 Symptoms leading to inability to feed orally; need for
administration of intravenous fluids, enteral or parenteral
nutrition; unstimulated saliva flow <0,1 ml/min.
Fonte. World Health Organization. Nacional Cancer Institute. Common
Terminology Criteria for Adverse Events [16]
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Statistical analysis
A descriptive analysis was performed on the sociodemo-
graphic characteristics and oral manifestations of the
participants at the three study stages, according to their
respective frequencies and percentages. The Kappa stat-
istic was used to measure concordance in cases in which
a particular individual presented an oral manifestation at
the next stage.
McNemar’s test was used to verify changes in the
number of cases of oral manifestations (direction of dis-
agreement) between stages. A significance level of 5 %
was adopted, and the software used in all analyses was
IBM (SPSS) version 21.
All parents or guardians of the participants signed the
consent form and previously clarified data collection.
The study was approved on 20 February 2013 by the Re-
search Ethics Committee of the Health Sciences Center
(Health Sciences Center) of the Federal University of
Espirito Santo (Federal University of Espirito Santo–
UFES) by the number opinion 201,117.
Results
Between the months April 2013 and 2014, a total of 66
children and adolescents were admitted to HEINSG di-
agnosed with cancer to make chemotherapy. In 15 of
these patients it was not possible to approach (Fig. 1).
The initial study population was composed of 51 indi-
viduals so.
The final sample size was 45 children and adolescents
at the second evaluation (1 month after the initial exam-
ination). It was not possible to follow six patients be-
tween the 1st and 2nd moments described in Fig. 1.
Table 2 shows the sociodemographic characteristics
and diagnosis of the 45 individuals monitored during the
study who were evaluated approximately 30 days after
the initial examination, showing that most of the indi-
viduals were in the 1- to 4-year-old age group (31.1 %),
were male (62.2 %), resided in greater Vitória (46.7 %),
Fig. 1 Deaths during the monitoring of patients at HEINSG
Table 2 Sociodemographic characteristics and diagnosis of 45
children and adolescents who were monitored in the study
(2013 and 2014, HEINSG)
Category Number Percent
Age group Less than 1 year 4 8.9
1 to 4 years 14 31.1
5 to 9 years 11 24.4
10 to 14 years 6 13.3
15 to 18 years 10 22.2




Greater Vitória–ES state 21 46.7
City in ES state (other
than the capital city)
18 40.0
Bahia state 4 8.9
Minas Gerais state 2 4.4











head (years of study)
0–4 years of study 4 8.9
4–8 years of study 18 40.0
8–12 years of study 12 26.7





0–4 years of study 3 6.6
4–8 years of study 15 33.3
8–12 years of study 10 22.2
More than 12 years
of study
16 35.5
Not known 1 2.0
Diagnosis Leukaemia 17 37.7
Lymphomas 10 22.2
Renal tumours 4 8.8




Bone tumours 2 4.4
Other 5 11.1
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belonged to socioeconomic class C (62.2 %), attended
school (73.3 %), and had up to 4 years of education
(24.4 %). Regarding the children’s and adolescents’ fam-
ilies, the heads of most households were fathers
(62.2 %). The education data clearly show that most
household heads had up to 8 years of education (40 %),
and most of the mothers had more than 12 years of edu-
cation (35.5 %).
Table 2 also shows that leukaemia was the most com-
mon diagnosis, occurring in 37.7 % of cases.
Table 3 shows the prevalence of oral complications
found during the clinical examinations conducted during
the two research stages. The prevalence of mucositis
considerably increased between the first and second
study stages, rising from 3.9 to 17.8 %. The prevalence
of Xerostomia considerably decreased between the first
and second stages, falling from 31 to 7.4 % of cases.
Table 4 shows the changes in oral manifestations be-
tween the first and second study stages. A reduction in
the number of cases of xerostomia was observed be-
tween the first and second stages, and the result of
McNemar’s test was very close to the significance level,
with a p-value of 0.06.
Discussion
Approximately 40 % of adult cancer patients and more
than 90 % of children under 12 years of age undergoing
cancer treatment have oral manifestations that directly
or indirectly arise from stomatotoxicities, such as muco-
sitis; xerostomia; fungal infections, such as candidiasis;
and viral infections, such as labial herpes simplex [7, 9].
Many national and international studies in the litera-
ture show a correlation between anticancer treatments,
particularly chemotherapy, and the occurrence of oral
complications in infant-juvenile patients and adults [8,
11, 18–27], and the magnitude of these side effects de-
pends on a number of factors related to the treatment,
tumour, and patient [23].
A less favored socioeconomic status is usually related
to a greater number of oral diseases such as caries, i.e., a
more unfavorable oral condition, which increases the
risk of oral manifestations during chemotherapy [34]. In
this study, however this association was not proven sta-
tistically, probably because patients studied belonged
mostly to classes B, C and D, with a greater concentra-
tion in class C, which made it difficult to compare the
classes. Our results therefore showed that oral manifes-
tations were not related to the socioeconomic status of
patients.
Oral mucositis is defined as an inflammation and ul-
ceration of the oral mucosa [28–32] and is one of the
most common and frequent lesions in cancer patients
undergoing chemotherapy. It is a major cause of pain
and also represents a distressing experience for cancer
patients [33, 34].
In this study, an increase in oral mucositis cases was
observed between the first and second stages. In
addition, mucositis was the most common oral manifest-
ation found in the clinical examination conducted 1
month after the beginning of chemotherapy. This result
is similar to those found in other studies [23, 24, 27, 35]
conducted in Brazil (Recife, Juiz de Fora, São José dos
Campos, and João Pessoa) and abroad (China). Other
authors [26] have observed mucositis percentages higher
than those found in this study. The results of research
conducted in São Luis (Brazil) [18] were different than
those of this study, as few cases of mucositis occurred
during anticancer treatment for leukaemia. This finding
was likely due to the small sample, which included only
12 individuals. The literature varies regarding the preva-
lence of oral mucositis induced by chemotherapy, which
has been reported to be 40 % [22], 65 % [33] and be-
tween 52 and 81 % [33]. However, in general, the results
reported in the literature have been higher than those
found in this study, which is likely due to favourable oral
health conditions before the initiation of treatment, with
a low percentage of oral diseases, which reduces the risk
of developing oral manifestations during treatment [7].
In this study, children and adolescents with various types
of cancer were examined, which may, to some extent, be




n % n %
Mucositis 2 3.9 8 17.8
Xerostomia 9 31 2 7.4
Cold sores 1 2 1 2.2
Candidiasis 2 3.9 4 8.9
Herpes simplex 0 0 1 2.2
Table 4 Changes in oral manifestations between the first and
second study stages
Stage 1 Stage 2 Kappa P value McNemar
P value
Yes No
Mucositis Yes 0 2 −0.077 0.999 0.109
No 8 35
Xerostomia Yes 2 5 0.369 0.065 0.063
No 0 19
Cold sores Yes 0 1 −0.023 0.999 0.999
No 1 43
Candidiasis Yes 2 0 0.646 0.006 0.500
No 2 41
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responsible for the low prevalence of mucositis, whereas
in studies concentrating solely on leukaemia patients,
generally speaking, a higher prevalence of oral manifes-
tations was encountered because leukaemia is charac-
terised by a high incidence of oral lesions during
treatment [35].
Tests used in this study for measuring salivary flow
were an adaptation of the standards proposed by the
World Health Organization for quantification of xeros-
tomia as a side effect of chemotherapy. Usually, authors
recommend saliva collection for 5 min to measure the
flow, but in adults [14]. In the present study, patients
evaluated were children and adolescents who showed a
severe general condition, sometimes incapacitating, so
we chose to perform this adaptation in sialometry test,
reducing saliva collection time.
In this study, the number of xerostomia cases declined
between the first and second stages. Different results
were found by other estudos [11, 24] of leukaemic pa-
tients [27] in which there was an increase in the number
of cases of xerostomia between stages. It is likely that in
this study, the reduction in xerostomia cases after the
start of chemotherapy (which was close to the signifi-
cance level, reaching 6 %) was due to the care given dur-
ing treatment, as an increased number of cases of
leukaemia can be observed among patients, and the ma-
jority of individuals with leukaemia remained hospita-
lised, received continuous intravenous hydration, and
also followed guidelines regarding the need for extensive
water and liquid intake in the first month of treatment.
A low prevalence of oral candidiasis was found in this
study, which is consistent with other studies [24] and
differs from the results obtained in one study [27] of leu-
kaemia patients. The low prevalence of oral candidiasis
(a result of the myelosuppression caused by chemother-
apy agents) was likely due to the use of antifungal drugs
that act topically and also systemic during the treatment
[35] of most patients. Antifungal medicaments used
were fluconazole 100 mg, once a day and nystatin,
three times daily. These medicaments were prescribed
by the hospital crew at the first signs of oral candid-
iasis, perhaps this influenced the low prevalence of this
disease. These antifungals are not known to cause salivary
flow reduction.
Patients with better oral health conditions and satisfac-
tory oral hygiene develop fewer oral manifestations, and
those conditions that do occur have a more rapid clinical
course [35]. Studies have reinforced the importance of
oral health for the prevention and reduction of oral
complications of cancer treatment [10, 31], so prior to
chemotherapy it is important to perform a Stomatologi-
cal evaluation and dental care to reduce infectious out-
breaks, such as removal of carious lesions and extensive
restorations, treatment of periodontal disease and even
tooth extractions in cases of teeth that require prolonged
treatment, as all infectious processes originated in the
oral cavity present a high risk of systemic infection,
which can lead to septic episodes in immunocompetent
patients compromised by oncologic therapy.
The presence of a dental surgeon working directly on
the medical team is essential for the prevention and
treatment of oral manifestations resulting from antineo-
plastic treatment. This dental surgeon can assist with
preventing the development of a more severe clinical
course, which can even result in the suspension of anti-
neoplastic treatment [24, 35, 36].
The sample size was a limitation of this study. However,
in Brazil, the observed percentage of paediatric tumours is
3 %, demonstrating the low prevalence of this disease,
which makes allocating a large number of individuals
difficult in a primary data study.
Conclusions
Based on the results observed in this study, it can be
concluded that oral manifestations were present, includ-
ing mucositis, which increased, and xerostomia, which
showed a reduction in the number of cases after the
start of chemotherapy. Oral complications, despite their
relatively low prevalence, were nonetheless present and
are among the most devastating complications in both
the short and long term, affecting basic human activities
such as eating and communicating. Furthermore, these
lesions may interfere with cancer treatment, causing
more serious infections or even sepsis.
The presence of an active dental surgeon on the multi-
disciplinary oncology team is therefore indispensable, as
they can assist in the prevention, early diagnosis, and
treatment of oral manifestations. A dental surgeon can
prevent lesions from escalating, thereby improving the
patient’s quality of life during treatment.
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